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Introduction: Diabetic patients are at high 
risk for coronary artery disease (CAD), which 
is the leading cause of death in this population.
The Swiss Society of Endocrinology-Diabetology
(SSED) recommends CAD screening for diabetic
patients with ≥2 additional cardiovascular risk fac-
tors (CVRF), by stress echocardiography (SE) or
myocardial perfusion imaging (MPI). The aim of
this study was to assess the application of these
guidelines and the treatment of CVRF in the dia-
betes outpatient clinics of the five Swiss University
Hospitals.
Methods: The study was initiated in Lausanne
and the study questionnaires were circulated to the
endocrinologists of the five Swiss University Hos-
pitals. Practitioners were asked to include consec-
utive patients attending the diabetes outpatient
clinics over one month. Prevalence of CAD,
screening methods for CAD, prevalence of CVRF,
biological analyses over the last 6 months and med-
ical therapy were recorded. 
Results: A total of 302 subjects were included.
The mean age was 53 ± 14 years, 68% had type 2
diabetes, 27% type 1 and 5% other types. Among
T2DM with ≥2 CVRF, 45% were screened for
CAD according to SSED guidelines. In T2DM
25% had blood pressure ≤130/80 mm Hg, 15% a
lipid profile within target, 23% HbA1c ≤7.0%.
Overall, 2% achieved all 3 targets.
Conclusions: Only 45% of T2DM with ≥2
CVRF were screened for CAD according to SSED
guidelines and 2% of T2DM had proper control
over all CVRF. Efforts are still necessary to im-
prove CAD prevention and screening of diabetic
patients in Swiss University Hospitals.
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The prevalence of coronary artery disease
(CAD) in diabetic patients is 2–4 times that in the
general population [1], and CAD is the leading
cause of death in those patients. Furthermore, type
2 diabetic patients (T2DM) with no history of 
myocardial infarction are at the same risk as non-
diabetic patients with a previous myocardial in-
farction [2], a view which, however, is not unani-
mous [3]. In addition, CAD more often has a silent
course in diabetic patients (20–30% compared to
10–20% in the general population [4, 5]). These
findings suggest that diabetes is a major cardiovas-
cular risk factor (CVRF) and that screening of
asymptomatic diabetic patients for CAD may be
useful. Systematic screening guidelines were first
proposed by the French Diabetes Association
(ALFEDIAM) in 1995 [6], which recommended
screening of T2DM with at least one additional
CVRF. In 1998, the American Diabetes Asso-
ciation (ADA) also recommended the screening of
T2DM with at least two additional CVRF [7]. 
In 2000, the Swiss Society of Endocrinology-Dia-
betology (SSED) proposed the same screening
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pattern as ADA, viz. by stress echocardiography
(SE) or myocardial perfusion imaging (SPECT-
MPI) [8]. On the other hand, many pharmacolog-
ical treatments for CVRF have proved to be highly
cost effective in this high risk population [9]. In this
context, the present survey sets out to assess the
application of systematic screening guidelines for
CAD and the form assumed by treatment of CVRF
in the five Swiss University Hospitals.
Methods
Study design
A retrospective and observational survey was drawn
up to evaluate the management of CVRF, follow-up of
CAD and the application of CAD screening guidelines in
diabetic patients in Switzerland. The main investigating
centre was the diabetes unit of Lausanne University Hos-
pital. 
Questionnaires were circulated to endocrinologists in
the diabetes outpatient clinics of the five Swiss University
Hospitals (Basel, Bern, Geneva, Lausanne and Zürich).
Each of these centres received 150 questionnaires in Eng-
lish (Appendix 1), and were requested to return them after
one month (between September and December 2003).
The number of completed questionnaires for each hospi-
tal was 72 in Basel, 15 in Bern, 71 in Geneva, 102 in Lau-
sanne and 42 in Zürich. Recruitment comprised consecu-
tive patients over one month. The questionnaires were
completed with regard to current treatment and CAD
screening.
The questions focused on the presence of CAD,
micro- and macrovascular complications of diabetes and
CVRF. If systematic screening for CAD was performed,
we requested information on strategy and reference. Data
on treatments before and after CAD screening were col-
lected. A qualitative question on the patient’s presumed
compliance was asked (yes or no). The rate of incomplete
replies was also recorded. 
Definitions
The usual definition of diabetes was used: fast plasma
glucose >7 mmol/l and plasma glucose >11 mmol/l. Obe-
sity was defined as a body mass index (BMI) ≥30 kg/m2,
sedentarity as physical activity <2 hours 30 minutes of
walking per week, and family history of premature CAD
as the occurrence of an event in parents or relatives aged
<55 years in men and <65 years in women. 
Patients
Any diabetic patient who attended one of the diabetes
outpatient clinics was included in the study. There was no
exclusion criterion.
Analysis
CVRF were evaluated, and a CAD screening score
was worked out on the basis of the CAD screening crite-
ria in the ADA and SSED guidelines [7, 8]. CVRF were
hypertension, obesity, family history of premature CAD,
sedentarity, current or former smoking and age >45 years.
Two cardiovascular risk markers were also included, viz.
lower limb arteriopathy and nephropathy. These guide-
lines suggest screening for CAD by non-invasive tests
when the “screening score” is equal to or higher than 
2 points: 2 points are given for lower limb arteriopathy 
and 1 point for nephropathy, hypertension, obesity, family
history of premature CAD, sedentarity, current or former
smoking and age ≥45 years.
The targets for CVRF, diabetes control and treat-
ment of microalbuminuria were defined according to 
the Swiss guidelines and to the Steno-2 study: systolic
blood pressure ≤130 mm Hg, diastolic blood pressure
≤80 mm Hg, total cholesterol ≤5.0 mmol/l, HDL-choles-
terol ≥1.0 mmol/l, LDL-cholesterol ≤2.6 mmol/l, triglycer-
ides ≤1.7 mmol/l, HbA1c ≤7.0% or 6.5%, urine albumin/
creatinine ratio: ≤3.5 mg/mmol in women and ≤2.5 mg/
mmol in men, albuminuria/24 hours <30 mg/24 h) [8–10].
Statistical analysis 
Descriptive statistical and univariate analyses were
performed. Categorical variables were expressed with fre-
quency and differences between groups were based on chi-
square test when appropriate. Continuous variables, nor-
mally distributed, were expressed in means and standard
deviation. Non-normally distributed continuous variables
were expressed by the median, 25th–75th percentiles, and
analysed by non-parametric statistics: Mann-Whitney
rank sum test and Wilcoxon signed-rank test. Statistical
significance was defined by p <0.05. Data analysis was
done with JMP 5.0 software (SAS Institute, Cary, USA).
Sponsorship 
This survey was sponsored by MSD; the authors for-
mulated the study design and results on a fully independ-
ent basis.
Results
Baseline characteristics
The main patient characteristics are shown in
table 1. Between September and December 2003,
302 surveys were received out of a total of 750
questionnaires distributed (40% response rate).
Mean age was 53 ± 14 years for the total study
population. T1DM were aged 43 ± 16 years and
T2DM 57 ± 11 years. A positive history of CAD
was found in 5% (n = 4) of T1DM and in 20% 
(n = 41) of T2DM.
Incomplete answer rates varied between 1%
for diabetes type and 14% for systematic screen-
ing rate. 
CAD screening was performed by SE,
SPECT-MPI or stress ergometry in 42% (n = 127)
of the whole study population, in 52% (n = 106) of
T2DM and 20% (n = 16) of T1DM. The strategy
of CAD screening in T2DM with ≥2 CVRF is
shown in table 2. Screening rate increased with the
screening risk score (data not shown).
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The prevalence of CVRF in T1DM and
T2DM is reported in table 3. The incomplete an-
swer rate was 24% in T1DM and 2% in T2DM.
The median CAD screening score yielded 
4 points (1–7) in the whole study population, 
1 point (0–5) in T1DM and 4 points (1–7) in
T2DM. In T2DM 87% had ≥2 points. 
The absolute cardiovascular risk in our total
population was 18.4% to 10 years according to 
the UPKDS risk engine (available data for 196/
302 patients). 
Therapy 
Medication of T1DM and T2DM is reported
in figure 1. The prescription rate of aspirin was
73% (n = 30) in T2DM for tertiary prevention
(post CAD) and 41% (n = 79) for secondary pre-
vention, if the patient had ≥2 CAD risk points.
In figure 2 we evaluated the rate of T2DM who
reached the objectives of the Steno-2 study inter-
vention group [9]. 13% had an HbA1c value ≤6.5%
and 23% ≤7.0%. 24% had blood pressure <130/
80 mm Hg. The percentage with lipids meeting
the recommendations (total cholesterol <5 mmol/l
and LDL-cholesterol <2.6 mmol/l) was 49%.
Taken together, all the targets of this study were
achieved in 1% of patients (n = 1) if HbA1c ≤6.5%
and 2% (n = 5) if HbA1c ≤7%.
Table 1
Baseline characteris-
tics (n = 302).
All patients Prevalence
mean or median value
Age (years) * 53 (± 14)
Males 67%
Type 1 diabetes 27%
Type 2 diabetes 68%
Other types of diabetes 5%
Diabetes duration (years)‡ 8 (3–15)
CAD+ 16%
Weight 84 (± 20)
BMI 29 (± 7)
Waist 107 (± 14)
Number of questionnaires/centre‡ 71 (15–102)
Type 1 diabetic patients
HbA1c (%)‡ 7.7 (7.0–8.4)
SBP (mm Hg)* 124 (± 7) 
DBP (mm Hg)* 75 (± 12) 
Total cholesterol (mmol/l)* 4.8 (± 1.1)  
LDL cholesterol (mmol/l)* 2.7 (± 1.0) 
HDL cholesterol (mmol/l)* 1.6 (± 0.6) 
Triglycerides (mmol/l)‡ 1.0 (0.7–1.4)
Type 2 diabetic patients
HbA1c (%)‡ 7.7 (7.0–8.6)
SBP (mm Hg)* 134 (± 17) 
DBP (mm Hg)* 79 (± 9)
Total cholesterol (mmol/l)* 4.7 (± 1.1) 
LDL cholesterol (mmol/l)* 2.6 (± 1.0)
HDL cholesterol (mmol/l)* 1.2 (± 0.3)
Triglycerides (mmol/l)‡ 1.9 (1.2–2.9)
* Mean (+ SD)   ‡ Median (p10-p90)
SBP: systolic blood pressure
DBP: diastolic blood pressure
Centres Basel Bern Geneva Lausanne Zürich Total
(n = 42) (n = 11) (n = 42) (n = 79) (n = 19) (n = 193)
SE 2% 9% 0% 46% 5% 20%
SPECT-MPI 14% 0% 36% 33% 5% 24%
Exercise stress testing 5% 45% 17% 4% 11% 10%
ECG at rest 22% 0% 42% 1% 21% 17%
Presence of symptoms 40% 9% 0% 4% 0% 11%
No screening 17% 37% 5% 12% 58% 17%
Table 2
CAD screening in
T2DM with ≥2 CVRF.
Discussion
Many guidelines for CAD screening in dia-
betic subjects have been published. However, no
study has yet evaluated adherence to these new
recommendations in tertiary centres. This survey
aims to assess the application of screening guide-
lines and treatment of CVRF in the outpatient
diabetes clinics of the five Swiss University Hospi-
tals.
CAD screening
In our survey, the screening rate in T2DM
with ≥2 CVRF was 54% by SE, SPECT-MPI or
exercise stress testing and only 26% in T1DM with
≥2 CVRF. Methods used and screening rates in the
5 University Hospitals were heterogeneous. In
T2DM with ≥2 CVRF, Basel screened only 21%
of its patients according to recent guidelines (by
SE, SPECT-MI or exercise stress testing), and the
majority (14%) by SPECT-MPI. In Zürich, these
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subjects were screened predominantly by exercise
stress testing (11% of patients). Bern preferred
stress ergometry (45%) and SE (9%). Geneva
screened essentially by SPECT-MPI (36%) and
exercise stress testing (17%) and Lausanne by SE
(46%) and SPECT-MPI (33%). Moreover, 28% of
all type 2 diabetic patients with ≥2 CVRF were
screened for CAD by an ECG at rest or by symp-
toms alone, and 17% were not screened at all. 
If we compare the screening rates in French-
and German-speaking Switzerland, we observe
that 85% of T2DM patients in Geneva and Lau-
sanne were screened by SE, SPECT-MI and exer-
cise stress testing versus only 31% in Basel, Bern
and Zürich (p <0.005). A plausible explanation is
that the ALFEDIAM CAD screening report was
published in French in 1995, the implementation
of CAD screening being of longer standing in
French-speaking than in German-speaking
Switzerland despite the high absolute risk for CAD
(18.4% at 10 years). The Swiss CAD screening
guidelines were published five years later in 2000.
We observed that the screening rate was pro-
portional to the number of CVRF (data not
shown). However, the recently published DIAD
study demonstrated that the traditional CVRF
were not significantly predictive of abnormal tests
[11].
Several hypotheses may explain the low rate of
CAD screening in these university centres. First,
the efficiency of these guidelines in patients with
asymptomatic CAD is low. In a previous study
done in Lausanne we analysed the rate of positive
screening tests when systematic CAD screening
was performed in T2DM with ≥2 CVRF, accord-
ing to SSED guidelines. In our study population
of 154 patients, only 20% presented a positive non-
invasive screening test (SE or SPECT-MPI) [12];
thus, 5 patients need to be screened to detect one
with ischaemia. In the DIAD study, the prevalence
of positive SPECT-MPI was 22% in a population
of 522 T2DM with ≥2 CVRF [11]. These findings
suggest that new strategies are needed to increase
the efficiency of these guidelines, and to select pa-
tients at higher risk of CAD in order to decrease
the number needed to screen. The second hypoth-
esis for the low screening rate is that thus far there
has been no study evaluating the capacity of sys-
tematic CAD screening to reduce cardiovascular
mortality in these subjects. Indeed, some experts
consider diabetes as an equivalent of CAD, and
that diabetic patients should be treated aggres-
sively for CVRF, independently of the presence of
CAD [9]. Finally, it appears that in Switzerland the
network between endocrinologists and cardiolo-
gists is not well developed. This suggests that we
should develop the same strategy as in France,
where there is a consensus between the cardiolo-
gists and endocrinologists who have published rec-
ommendations for CAD screening [13].
Management of cardiovascular risk factors
Another important issue in T2DM is preven-
tion of cardiovascular complications by treating
CVRF. Management of hyperglycaemia has shown
a reduction in microvascular complications in
T2DM [14] and treatment of hypercholesterol-
aemia with a statin has been shown to reduce mor-
tality in patients with CAD [15, 16]. The Steno-2
study demonstrated that intensive treatment of all
CVRF reduced the risk of cardiovascular compli-
cations by more than 50% in T2DM after 8 years
of follow-up (number needed to treat = 5) [9]. If 
we compare our data with the Steno-2 study, we
observe that 13% of our T2DM had an HbA1c
≤6.5% versus 15% in the Steno-2 study popula-
tion. The lipid pattern and blood pressure control
were also better in the Steno-2 study. Neverthe-
less, these 2 studies cannot be compared directly
because the Steno-2 study was an interventional
monocentric study whereas ours was an observa-
tional multicentric study. In the EUROASPIRE
survey [17], the aim was to evaluate the control of
CVRF in a population of 5556 patients with CAD
in 15 European countries. In this study, which was
also observational and multicentric, the prevalence
of CVRF was high and the therapeutic goals hard
Diabetes type T1DM T2DM
Hypertension 32% 72%
Dyslipidaemia 32% 72%
Obesity 5% 53%
Family history of premature CAD 6% 10%
Sedentarity 17% 46%
Current / former smoking 16%/10% 22%/21%
Table 3
Prevalence of CVRF
in T1DM and T2DM.
Figure 1
Treatment of
diabetes and CVRF. 
1. Oral anti-diabetic
drugs
2. Insulin
3. ACE inhibitors
4. AT2 receptor
antagonists
5. Beta-blockers
6. Ca2+ antagonists
7. Diuretics
8. Aspirin
9. Anticoagulation
10. Lipid lowering
agents
Figure 2
Percentage of T2DM
reaching the targets
according to the
Steno-2 study objec-
tives. Objectives:
HbA1c ≤6.5%; 
total cholesterol 
≤5.0 mmol/l; triglyc-
erides ≤1.7 mmol/l;
SBP ≤130 mm Hg;
DBP ≤80 mm Hg.
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to achieve, and only 62% of T2DM had a total
cholesterol ≤5.0 mmol/l.
Finally, these results illustrate the physicians’
difficulty in applying evidence-based medicine
from well structured clinical trials in tertiary dia-
betes reference centres. Many elements may influ-
ence the decision to screen or to treat. Freeman et
al. [18] reported that practioners are influenced 
by previous experience and feelings (about the 
patient, about the evidence itself or where the 
evidence has come from), and by the physician-
patient relationship.
Study limitations
It could be argued that a survey of 302 diabetic
patients may not reflect the follow-up of the dia-
betic population in Switzerland. However, the 
St Vincent Declaration showed that a survey of 
this kind is globally reproducible in time [19]. The
wide disparity in the number of questionnaires
completed at each University Hospital is more
disturbing, because the proportion of completed
questionnaires at each centre affects global results.
Out of the 150 questionnaires sent to every dia-
betology outpatient clinic the median rate of com-
pleted questionnaires was 40%. This survey did
not investigate the reasons for weak guideline ad-
herence, nor the control efficiency of CVRF. 
Conclusion
Despite a high cardiovascular risk in the dia-
betic population, the rates of systematic CAD
screening and CVRF control are not optimal. This
survey illustrates the difficulty for diabetes special-
ists of transferring guidelines into everyday clini-
cal practice. Moreover, the issues on screening ef-
ficiency and the expected benefit of systematic ap-
plication of guidelines have not yet been resolved
on the individual level for the asymptomatic
diabetic patient. A recent study suggested that
systematic CAD screening in diabetic patients may
reduce cardiovascular mortality [20]. The 140 pa-
tients of this study were either systematically
screened for CAD or had follow-up visits for 
4 years. Mortality was lower in the patients
screened for CAD. However, it remains unre-
solved whether the best strategy is to treat every
CVRF aggressively (Steno-2 study [10]) or to
screen diabetic patients with ≥2 CVRF systemati-
cally for CAD .
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Appendix 1
Questionnaire.
Patient # _________ University _________
Gender     male            female Current date  ____/____/ 2003
Date of birth      ____/____/______ Patient considered compliant:    yes    no
Diagnoses
Type of diabetes  2    1    other _______ Year of diagnosis _______
Coronary artery disease  yes   no Interventions
 Asymptomatic
 Typical angina pectoris Date _______  Coronary artery bypass Date _______
 Atypical angina pectoris Date _______  PTCA / Stent Date _______
 Myocardial infarction Date _______
Coronary artery disease screening mode Lower limb arteriopathy
 Resting ECG     Symptoms +  Ergometry  No   Yes    Unknown Date _______
 Stress echocardiography   Scintigraphy
Systematic screening for CAD  Yes     No Cerebrovascular disease
Screening guidelines  ADA  Swiss   Other  No   Yes    Unknown Date _______
Cardiovascular risk factors
 Hypertension  Family history of premature coronary artery   
 Hyperlipidaemia  (<55 years /<65 years)
 Currently smoking    Former    Never  Sedentarity (<2h30 of walk / week)
 Obesity (BMI >30 kg/m2)
Complications of diabetes
Nephropathy  No Retinopathy  No  Background  Pre-prolif.
 Microalbuminuria  Proliferative  Blind
 Macroalbuminuria Neuropathy  No  Sensitive  autonomous
 Renal insufficiency  Impotence  Unknown
 Unknown Lower limb  No  Yes
amputation
Biological analyses of the last 6 months
Plasma creatinine _________  mmol/l Microalbuminuria ________  mg/24h or
Total cholesterol _________  mmol/l Microalb/creatininuria ________  mg/mmol
LDL-C _________  mmol/l Weight ________  kg
HDL-C _________  mmol/l Height ________  cm
Triglycerides _________  mmol/l Waist ________  cm
Blood pressure ____/____   mm Hg Hip ________  cm
HbA1c _________  %
Treatments Before screening After screening
Drug / Dosage Drug / Dosage
 Oral antidiabetic 1 _________________/______ _________________/______
 Oral antidiabetic 2 _________________/______ _________________/______
 Oral antidiabetic 3 _________________/______ _________________/______
 Insulin        Nb injections/j ______ _________________/______ _________________/______
 Insulin 2     Nb injections/j ______ _________________/______ _________________/______ 
 ACE inhibitor _________________/______ _________________/______
 AII receptor antagonist _________________/______ _________________/______
 Beta blocker _________________/______ _________________/______
 Calcium antagonist _________________/______ _________________/______
 Diuretic _________________/______ _________________/______
 Aspirin _________________/______ _________________/______
 Anticoagulant _________________/______ _________________/______
 Lipid lowering _________________/______ _________________/______
Reason why no lipid lowering drug was prescribed ______________________________________________
Reason why no antihypertensive drug was prescribed ______________________________________________
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